Ping An Research on AI Applications for retinal imaging selected at medical imaging conference

Ping An Smart Healthcare cooperated with Optovue to develop multiple AI OCT products

AI Applications, OCT products, Smart Healthcare, Ping An Insurance, Ping An Insurance (Group) Company of China, ENT Hospital of Fudan University

Ping An Insurance (Group) Company of China, Ltd. announced hat five papers related to artificial intelligence (AI) technology in ophthalmic imaging by its smart city's smart health care team (Ping An Smart Healthcare) have been accepted by the top international medical imaging conference, the International Symposium on Biomedical Imaging (ISBI) 2020. ISBI is sponsored by the Institute of Electrical and Electronics Engineers (IEEE).

The Ping An papers cover various smart tasks related to the diagnosis of eye diseases, including quality control, screening, lesion detection, segmentation and quantization of retinal structure or lesion areas. The ISBI is one of the world's top academic conferences dedicated to mathematical, algorithmic and computational aspects of biological and biomedical imaging.

Ping An Smart Healthcare is affiliated with Ping An Smart City, a subsidiary of the Group. It uses the Group's three core technologies -- AI, blockchain and cloud computing -- to provide integrated diagnosis and treatment solutions. It includes elements such as smart triage and guidance, smart disease prevention, smart medical imaging screening/ diagnosis and smart clinical decision support.

In addition to the papers to be presented at ISBI, Ping An Smart Healthcare's AI Optical Coherence Tomography (OCT) screening system proposed in papers has completed clinical validation in numerous hospitals.

From 2018 to 2019, Ping An Smart Healthcare cooperated with Optovue, an internationally renowned OCT manufacturer, to develop multiple AI OCT products. The AI OCT screening system completed clinical validation in the Eye & ENT Hospital of Fudan University, Shanghai General Hospital and Shanghai Tenth People's Hospital at the beginning of 2019, and recently completed clinical validation in multiple prestigious hospitals, including Peking Union Medical College Hospital, the University of Hong Kong, Qingdao Eye Hospital and Shandong Eye Hospital.